Enzychem Lifesciences엔지켐생명과학
183490 · KOSDAQ · ₩183490 · 엔지켐생명과학
- Market cap
- ₩84B
- Enterprise value
- ₩70B
- P/E
- —
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- −12.3%
- Net margin
- −26.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−43.9% from the high
₩966Today: ₩990 – ₩990₩1,766
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD−35.3%
- 1Y−2.4%
- Volume today
- —
- Traded today
- —
- Listed shares
- 84,640,235
- EPS (12 months)
- −₩213
- Earnings yield −21.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: The filing title is neutral and gives no outcome, so the tone is neutral. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Enzychem Lifesciences stock overview
Enzychem Lifesciences (엔지켐생명과학, KRX: 183490) is listed on KOSDAQ, in the Biotech & Pharma sector. Enzychem Lifesciences is a Korean biopharmaceutical company with three main business segments: global new drug development, active pharmaceutical ingredients (APIs), and health functional foods, plus a subsidiary, Sinheung Industry, which produces bio-oils used as feedstock for HVO renewable diesel and sustainable aviation fuel (SAF). Its shares closed at ₩990 on Oct 30, 2026, unchanged on the day, giving it a market value of ₩84B.
Key facts
- Market cap
- ₩84B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 30, 2026
- Main business
- Enzychem Lifesciences is a Korean biopharmaceutical company with three main business segments: global new drug development, active pharmaceutical ingredients (APIs), and health functional foods, plus a subsidiary, Sinheung Industry, which produces bio-oils used as feedstock for HVO renewable diesel and sustainable aviation fuel (SAF).
Quick answers about Enzychem Lifesciences
- What does Enzychem Lifesciences do?
- Enzychem Lifesciences is a Korean biopharmaceutical company with three main business segments: global new drug development, active pharmaceutical ingredients (APIs), and health functional foods, plus a subsidiary, Sinheung Industry, which produces bio-oils used as feedstock for HVO renewable diesel and sustainable aviation fuel (SAF). Its drug development pipeline targets chemo-radiation induced oral mucositis, acute radiation syndrome, and atopic dermatitis, and it exports its API products such as expectorants, contrast agents, and anticoagulants to countries including China, India, Russia, the UK, and Singapore. Its manufacturing facilities are located in Jecheon and Ansan in South Korea.
- What is the market cap of Enzychem Lifesciences?
- The market capitalisation of Enzychem Lifesciences was ₩84B at the close on Oct 30, 2026.
- Who are the largest shareholders of Enzychem Lifesciences?
- According to the latest official filings, the largest reported holders are Bridget Life Sciences (21.61%, as of Oct 15, 2026); Yoon Yeong-bae (10.26%, as of Apr 6, 2026); Nam Yun-hee (5.98%, as of Jun 5, 2026).
- When is the next earnings report from Enzychem Lifesciences?
- Korean companies rarely announce results dates in advance. Based on when Enzychem Lifesciences filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Enzychem Lifesciences?
- Yes. The National Pension Service held 0.30% of Enzychem Lifesciences shares as of Dec 31, 2021.
Company profile
Enzychem Lifesciences is a Korean biopharmaceutical company with three main business segments: global new drug development, active pharmaceutical ingredients (APIs), and health functional foods, plus a subsidiary, Sinheung Industry, which produces bio-oils used as feedstock for HVO renewable diesel and sustainable aviation fuel (SAF). Its drug development pipeline targets chemo-radiation induced oral mucositis, acute radiation syndrome, and atopic dermatitis, and it exports its API products such as expectorants, contrast agents, and anticoagulants to countries including China, India, Russia, the UK, and Singapore. Its manufacturing facilities are located in Jecheon and Ansan in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 엔지켐생명과학
- Sector
- Biotech & Pharma
- CEO
- 손기영
- Founded
- Jul 1999
- Listed
- Feb 2018
- Listed shares
- 84,640,235
- Fiscal year ends
- Month 12
- Website
- www.enzychem.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Lawsuit filed or ruledOct 29, 2026
- 5%+ holding reportOct 15, 2026
- Lawsuit filed or ruledSep 11, 2026
- Confirmation of Facts Such as Adverse Opinion on Semi-annual Review (Audit), Including Capital Impairment Ratio of 50% or More or Equity Under ₩1BAug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Enzychem Lifesciences / 엔지켐생명과학 / 183490 / KRX:183490
Source: KRX statistical information